Is ProShares Ultra Nasdaq Biotechnology halal to invest in?

As of September 2026, ProShares Ultra Nasdaq Biotechnology BIB is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is ProShares Ultra Nasdaq Biotechnology a Shariah-compliant ETF?

An ETF is considered Shariah-compliant if its underlying assets consist primarily of companies that operate in permissible business activities and meet Islamic financial screening thresholds. Musaffa analyzes ProShares Ultra Nasdaq Biotechnology using these criteria to determine its compliance status.

How often is the Shariah compliance for ProShares Ultra Nasdaq Biotechnology updated?

The Shariah compliance status of ProShares Ultra Nasdaq Biotechnology may be updated periodically when new portfolio disclosures, financial statements of underlying companies, or other relevant information becomes available.

Can a halal ETF like ProShares Ultra Nasdaq Biotechnology become non-compliant?

Yes. An ETF that is currently Shariah-compliant may become non-compliant if its underlying holdings change or if the financial ratios of the companies within the fund exceed Shariah thresholds.

Where can I check the Shariah status of ProShares Ultra Nasdaq Biotechnology?

You can check the latest Shariah compliance status of ProShares Ultra Nasdaq Biotechnology on Musaffa's ETF page, where screening results and key indicators are updated to help Muslim investors make informed decisions.

ProShares Ultra Nasdaq Biotechnology BIB

BIB Shariah Compliance

Screening Methodology: AAOIFI

As of September 2026, ProShares Ultra Nasdaq Biotechnology is classified as not halal.

NOT HALAL

Is ProShares Ultra Nasdaq Biotechnology ETF Halal?

Shariah Compliance Analysis of BIB ETF

US Equity Health Care

No. As of September 2026, ProShares Ultra Nasdaq Biotechnology (BIB) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. ProShares Ultra Nasdaq Biotechnology does not pass Musaffa's business and financial screening criteria.

BIB was created on 2010-04-07 by ProShares. The fund's investment portfolio concentrates primarily on health care equity. BIB provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ.

ProShares Ultra Nasdaq Biotechnology (BIB) Chart

Key Statistics of ProShares Ultra Nasdaq Biotechnology (BIB)

Today's Open

AUM

Avg. Volume

Expense Ratio

P/E Ratio

P/B Ratio

Sector Exposure

Other
72.33%
Health Care
27.67%

FAQ's for ProShares Ultra Nasdaq Biotechnology (BIB)

As of September 2026, ProShares Ultra Nasdaq Biotechnology BIB is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
An ETF is considered Shariah-compliant if its underlying assets consist primarily of companies that operate in permissible business activities and meet Islamic financial screening thresholds. Musaffa analyzes ProShares Ultra Nasdaq Biotechnology using these criteria to determine its compliance status.
The Shariah compliance status of ProShares Ultra Nasdaq Biotechnology may be updated periodically when new portfolio disclosures, financial statements of underlying companies, or other relevant information becomes available.
Yes. An ETF that is currently Shariah-compliant may become non-compliant if its underlying holdings change or if the financial ratios of the companies within the fund exceed Shariah thresholds.
You can check the latest Shariah compliance status of ProShares Ultra Nasdaq Biotechnology on Musaffa’s ETF page, where screening results and key indicators are updated to help Muslim investors make informed decisions.